Two Struggling Biotechs Just Fused Into a $125M Bet on a Disease Nobody Can Cure
Two small biotechs just merged into Fibrx Therapeutics with $125 million in financing to tackle fibrosis, one of medicine's most stubborn unsolved problems. The catch? Original Skye shareholders got diluted down to just 5.38% of the new company.
A Company Born From Desperation (and Maybe Genius)
Imagine two restaurants, both struggling to fill tables, deciding to merge into one big place with a singular focus: the best damn pizza in town. That's roughly what just happened in biotech.
Skye Bioscience and U.K.-based Redx Pharma announced on August 14 that they're combining to form a brand-new public company called Fibrx Therapeutics. The deal comes packaged with approximately $125 million in financing, giving the newborn company enough cash to fund operations into 2029. The combined entity will trade on Nasdaq, and it's going all-in on one of medicine's most stubborn problems: fibrosis.
But before you pop the champagne, consider this: existing Skye shareholders will own just 5.38% of the new company. Financing investors, meanwhile, walk away with roughly 48.45%. That's not a merger so much as a takeover dressed in a tuxedo.
What Even Is Fibrosis, and Why Should You Care?
Fibrosis is what happens when your body's wound-healing process goes haywire. Instead of patching up damage and moving on, the body keeps laying down scar tissue until organs stop working properly. Think of it like a contractor who shows up to fix a crack in your wall and never leaves, eventually filling your entire house with drywall.
It can hit your lungs, liver, kidneys, and gut. And despite decades of research, the medicine cabinet is embarrassingly bare. For the most common form, idiopathic pulmonary fibrosis (IPF), approved drugs include pirfenidone, nintedanib, and nerandomilast. None of them can reverse the disease. They just slow it down. Many patients who are eligible for treatment don't even receive it, thanks to access and tolerability barriers.
That enormous gap between patient need and available therapy is exactly what Fibrx is betting its entire existence on.
Follow the Money
The $125 million headline number actually comes from several different buckets of capital, stitched together like a financial quilt.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The biggest piece is a ~$68 million private placement (known as a PIPE) led by a syndicate of investors including Abingworth, British Business Bank, NEXTBio Capital, 5AM Ventures, and Redmile. On top of that sits a $36 million Redx Series A financing, also led by Abingworth with participation from British Business Bank and Redmile.
Then there's a $22 million committed equity line facility from a Redmile-affiliated fund, plus a separate $5 million warrant. Add it all up and you get roughly $125 million in gross proceeds. It's a creative structure; the kind of deal that gets done when neither party has the balance sheet to go it alone.
For context, Skye's market cap sat at a meager $18.71 million as of August 10. Its stock had cratered 84.55% over the past year. This wasn't a company negotiating from strength. It was a company that needed a lifeline, and Redx's fibrosis pipeline was it.
The Drug That Could Make or Break Fibrx
The crown jewel of the combined pipeline is RXC008, a GI-restricted pan-ROCK inhibitor (a fancy way of saying it targets a specific enzyme pathway while staying mostly in the gut). It's being developed for fibrostenotic Crohn's disease, a particularly nasty form of Crohn's where scar tissue narrows the intestine, often requiring surgery.
RXC008 already has an open IND (the regulatory green light to test in humans) and FDA Fast Track designation, which can speed up development and review. Enrollment for a Phase 2 trial is expected to begin in Q4 2026, with topline data projected for the second half of 2028.
Behind RXC008 sits zelasudil (RXC007), a selective ROCK2 inhibitor that completed a Phase 2a study in IPF. But Redx isn't pushing zelasudil forward internally; it's being positioned for a partnership deal. Think of it as the asset in the shop window, waiting for a bigger company to adopt it.
Further back in the pipeline, a DDR inhibitor program targeting kidney, lung, and liver fibrosis is still in preclinical development, with an IND submission targeted for 2027. That one's also earmarked for partnering.
The Elephant in the Room: Dilution
Let's talk about the ownership math, because it tells a story the press release would rather you skim past.
Post-merger, Redx shareholders are expected to own about 46.17% of Fibrx. Financing investors get approximately 48.45%. And the original Skye shareholders? They're left holding 5.38%.
That's brutal. If you bought Skye stock hoping for upside, you just watched your ownership get diluted to a rounding error. The deal is structured as a U.K. scheme of arrangement (essentially a court-supervised merger mechanism), with Skye technically acquiring Redx. But the ownership numbers tell a different story. The investors and Redx shareholders are running this show.
Both boards unanimously approved the deal, which is expected to close in Q4 2026 pending shareholder votes, regulatory approvals, and sign-off from the High Court of England and Wales.
The Skye Bioscience Origin Story Is Wild
Skye wasn't always a fibrosis company. It wasn't even always Skye. The entity started life in 2011 as Load Guard Logistics, a Nevada corporation. It became Nemus Bioscience after a 2014 reverse merger, rebranded as Emerald Bioscience in 2019, then became Skye Bioscience in January 2021.
It later acquired Bird Rock Bio in 2023, moved to Nasdaq in April 2024, and pivoted toward metabolic disease with an obesity drug called nimacimab, which is currently in a Phase 2a study with topline data expected in Q4 2026. The company's three-year return of 87.37% looks impressive until you see the one-year cliff.
This is a company that has reinvented itself more times than Madonna. Whether this latest transformation sticks depends entirely on RXC008.
So, Will This Actually Work?
The bull case is straightforward: fibrosis is a massive, underserved therapeutic area with almost no competition on the pharmacy shelf. If RXC008 delivers strong Phase 2 data in fibrostenotic Crohn's disease, Fibrx could become an acquisition target or a legitimate standalone platform. The $125 million war chest provides runway through 2029, covering the Phase 2 readout and then some.
The bear case is equally clear. This is two small companies combining their weaknesses along with their strengths. The pipeline is early (Phase 2 at best, preclinical at worst). Skye shareholders got crushed on dilution. And financing investors owning nearly half the company means their interests will drive major decisions.
The fibrosis space needs a breakthrough. Whether Fibrx Therapeutics is the one to deliver it remains an open question. But at least now they've got the cash to try.
Deals & M&A
4 min read
BioCryst Just Killed Its Own Lab. Here's Why That Might Be Brilliant.
BioCryst is shutting down its 40-year-old internal drug discovery operation and betting everything on external deals. The rare-disease biotech is profitable, growing, and making a deliberate strategic gamble that could redefine what a mid-cap biotech looks like.
